Dhansa Labs

Which are the latest news on Dhansa Labs?

Why is Dhansa Labs Ltd falling/rising?

As of 05-Sep, Dhansa Labs Ltd's stock price is rising to 28.10, reflecting a 4.85% increase. The stock's short-term performance is strong, but long-term challenges, including high debt and declining investor participation, may impact sustainability.

As of 05-Sep, Dhansa Labs Ltd's stock price is rising, currently at 28.10, reflecting a change of 1.3 or 4.85% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 8.08% compared to the Sensex's decline of 1.15%. Additionally, the stock has shown significant growth over the past month, with a 41.21% increase, while the Sensex has decreased by 2.91%.<BR><BR>Despite a year-to-date decline of 36.21%, the company has reported a 20% increase in profits over the past year, which may contribute to a more favorable perception among investors. The stock's current performance today has also outperformed its sector by 3.93%. Furthermore, the company's valuation appears attractive with a Return on Capital Employed (ROCE) of 6.4 and a low Enterprise Value to Capital Employed ratio of 0.8.<BR><BR>However, it is important to note that there are concerns regarding long-term fundamental strength, as indicated by a high Debt to EBITDA ratio of 3.62 times and a weak growth rate in net sales and operating profit over the last five years. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 89.58% against the 5-day average. <BR><BR>In summary, while the stock is currently rising due to short-term performance and profit growth, underlying long-term challenges may affect its sustainability.

What does Dhansa Labs do?

Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry as a Micro Cap company, reporting net sales of 31 Cr and a net profit of 1 Cr for June 2026. The company has a market cap of INR 73 Cr and key financial metrics include a P/E of 13.00 and a debt-equity ratio of 0.38.

Overview:<BR>Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Ambey Laboratories Private Limited" in 1985 and later converted to a Public Limited Company, changing its name to "Ambey Laboratories Limited" in December 2014. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 31 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 73 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00 <BR>Industry P/E: 26 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.38 <BR>Return on Equity: 5.78% <BR>Price to Book: 0.71 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Dhansa Labs?

Dhansa Labs' peers include Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Bhaskar Agrochem, Super Crop Safe, Aimco Pesticides, Adarsh Plant, and Phyto Chem (I). In terms of performance, Dhansa Labs has a 1-year return of -32.43%, lower than all peers, with Bhaskar Agrochem showing the lowest return at 0.00% and Crop Life Scienc the highest.

Peers: The peers of Dhansa Labs are Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Bhaskar Agrochem, Super Crop Safe, Aimco Pesticides, Adarsh Plant, and Phyto Chem (I).<BR><BR>Quality Snapshot: Excellent management risk is observed at Bhaskar Agrochem, while Below Average management risk is found at Shivalik Rasayan, Super Crop Safe, Aimco Pesticides, Adarsh Plant, and Phyto Chem (I), and the rest. Average management risk is present at Crop Life Scienc and Aristo Bio-Tech. In terms of Growth, Good growth is noted at Bhaskar Agrochem, while Below Average growth is found at Shivalik Rasayan, Crop Life Scienc, Dhansa Labs, Super Crop Safe, Aimco Pesticides, Adarsh Plant, and Phyto Chem (I), and the rest. Average growth is observed at Aristo Bio-Tech. For Capital Structure, Excellent capital structure is seen at Shivalik Rasayan, while Below Average capital structure is noted at Crop Life Scienc, Dhansa Labs, Bhaskar Agrochem, Super Crop Safe, Aimco Pesticides, Adarsh Plant, and Phyto Chem (I), and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Crop Life Scienc at N/A, while the peer with the lowest 1-year return is Bhaskar Agrochem at 0.00%. Dhansa Labs has a 1-year return of -32.43%, which is lower than all peers. Additionally, all peers except for Aristo Bio-Tech and Crop Life Scienc have a six-month return of 0.00%.

How big is Dhansa Labs?

As of 31st August, Dhansa Labs Ltd has a market capitalization of 73.00 Cr, with net sales of 103.92 Cr and net profit of 3.63 Cr over the latest three quarters. Shareholder's funds are 76.35 Cr, and total assets are valued at 125.79 Cr as of March 2025.

As of 31st August, Dhansa Labs Ltd has a market capitalization of 73.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarterly performance, the sum of Net Sales for the latest three quarters is 103.92 Cr, while the sum of Net Profit for the same period is 3.63 Cr.<BR><BR>For the balance sheet snapshot, the reporting period is March 2025. The Shareholder's Funds amount to 76.35 Cr, and the Total Assets are valued at 125.79 Cr.

How has been the historical performance of Ambey Laborator.?

Ambey Laborator has shown steady growth in net sales, increasing from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, but faced a decline in profit after tax to 4.78 Cr in Mar'25. The company has negative cash flow from operating activities, indicating liquidity challenges, despite a significant inflow from financing activities.

Answer:<BR>The historical performance of Ambey Laborator shows a steady growth in net sales and total operating income over the past four years, with figures rising from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25. The total expenditure has also increased, reflecting higher raw material costs, which rose from 69.91 Cr in Mar'22 to 118.83 Cr in Mar'25. Operating profit, excluding other income, has fluctuated slightly, peaking at 11.50 Cr in Mar'25, while profit before tax increased to 6.04 Cr in the same period. However, profit after tax saw a decline to 4.78 Cr in Mar'25 from 7.72 Cr in Mar'24. The company's equity capital has grown significantly, reaching 24.95 Cr in Mar'25, and total liabilities increased to 125.79 Cr, driven by a rise in short-term borrowings. Cash flow from operating activities has been negative, indicating challenges in cash generation, while cash flow from financing activities has provided a net inflow of 48.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Ambey Laborator's financial performance has demonstrated a consistent upward trend in net sales, which increased from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, alongside total operating income that mirrored this growth. The company's total expenditure also rose, primarily due to escalating raw material costs, which climbed from 69.91 Cr to 118.83 Cr over the same period. Operating profit, despite some fluctuations, reached 11.50 Cr in Mar'25, contributing to a profit before tax of 6.04 Cr. However, profit after tax decreased to 4.78 Cr in Mar'25, down from the previous year's 7.72 Cr. The equity capital has notably increased to 24.95 Cr, while total liabilities surged to 125.79 Cr, largely due to a significant rise in short-term borrowings. The cash flow from operating activities has been negative, indicating potential liquidity issues, although cash flow from financing activities has provided a substantial inflow, reflecting the company's reliance on external financing to support its operations.

Is Ambey Laborator. overvalued or undervalued?

As of September 23, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.92 and an EV to EBITDA of 15.02, significantly underperforming with a -39.55% return compared to the Sensex's -2.97%.

As of 23 September 2025, the valuation grade for Ambey Laborator. has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.92, an EV to EBITDA of 15.02, and a ROE of 6.26%. <BR><BR>In comparison to its peers, UPL has a PE Ratio of 38.05 and an EV to EBITDA of 9.17, while P I Industries is also very expensive with a PE of 34.2 and an EV to EBITDA of 24.36. Ambey Laborator.'s valuation appears stretched relative to these peers, highlighting its overvaluation status. Notably, over the past year, the stock has underperformed with a return of -39.55%, contrasting sharply with the Sensex's decline of only -2.97%.

Who are the top shareholders of the Ambey Laborator.?

The top shareholder of Ambey Laborator is Sarina Gupta, holding 68.49% of the shares, with no pledged promoter holdings. Public shareholders include Nakshatra Stressed Assets Fund Scheme I at 1.65% and individual investors collectively holding 22.4%.

The top shareholders of Ambey Laborator are primarily the promoters, with Sarina Gupta holding the highest stake at 68.49%. There are no pledged promoter holdings. In terms of public shareholders, the highest is Nakshatra Stressed Assets Fund Scheme I, which holds 1.65%. Additionally, individual investors collectively hold 22.4% of the shares. There is also one foreign institutional investor (FII) with a very small holding of 0.01%.

What is the technical trend for Ambey?

As of May 19, 2025, Ambey's technical trend is mildly bearish, influenced by daily moving averages and OBV, despite a mildly bullish weekly MACD.

As of 19 May 2025, the technical trend for Ambey has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages and Bollinger Bands are both showing mildly bearish signals. The weekly KST is bearish, and the OBV is also mildly bearish. The Dow Theory shows no trend in both weekly and monthly time frames. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the OBV.

When is the next results date for Ambey?

No Upcoming Board Meetings

Has Ambey declared dividend?

No Dividend History Available